default author photo

Luis F. Lopez-Cortes

Virgen del Rocio University

SCHOLARLY PAPERS

2

DOWNLOADS

213

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Two-Year Longitudinal Profile of HIV-1 DNA/RNA Integrity, Immune Activation, and Inflammation in Treatment-Naïve People with HIV-1 Starting Dolutegravir/Lamivudine vs. Dolutegravir/Tenofovir Alafenamide/Emtricitabine: TRIDUNA Study

Number of pages: 28 Posted: 09 Dec 2024
Virgen del Rocio University, Virgen del Rocio University, Virgen del Rocio University, Virgen del Rocio University, University of Seville, Virgen del Rocio University, Virgen del Rocio University, Virgen del Rocio University, Hospital Juan Ramón Jiménez, University Hospital of Puerto Real, Carlos III Institute of Health, Instituto de Salud Carlos III - CIBER de Enfermedades Infecciosas (CIBERINFEC), Virgen del Rocio University, Virgen del Rocio University and Virgen del Rocio University
Downloads 131 (554,631)

Abstract:

Loading...

treatment-naïve patients, 2DR, 3DR, DTG/3TC & DTG/TAF/FTC

2.

Looking for the Optimal Timing of Administration of a Latency Reversing Agent to Impact on the HIV Reservoir Size

Number of pages: 21 Posted: 20 Nov 2024
Carlos III Institute of Health, Hospital Clínic de Barcelona, Universidad de Alcalá, IRYCIS, Hospital Clínic de Barcelona, Hospital Clínic de Barcelona, Universidad de Alcalá, IRYCIS, Hospital Clínic de Barcelona, Instituto de Salud Carlos III - CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III - CIBER de Enfermedades Infecciosas (CIBERINFEC), Hospital Universitari Son Espases, Universidad Europea de Madrid - Hospital Universitario Infanta Sofía, Santa Lucía University General Hospital, Virgen del Rocio University, Carlos III Institute of Health - National Center for Epidemiology, Universidad de Alcalá, IRYCIS, Hospital Clínic de Barcelona and Universidad de Alcalá, IRYCIS
Downloads 82 (790,029)

Abstract:

Loading...

Latency Reversal Agent, Timing of administration, HIV reservoir, Maraviroc, antiretroviral therapy